These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 18084154

  • 1. Temsirolimus (Torisel) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Dec 17; 49(1276):103-4. PubMed ID: 18084154
    [No Abstract] [Full Text] [Related]

  • 2. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
    Malizzia LJ, Hsu A.
    Clin J Oncol Nurs; 2008 Aug 17; 12(4):639-46. PubMed ID: 18676330
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA.
    Nat Clin Pract Oncol; 2008 Oct 17; 5(10):601-9. PubMed ID: 18607393
    [Abstract] [Full Text] [Related]

  • 4. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial.
    N Engl J Med; 2007 May 31; 356(22):2271-81. PubMed ID: 17538086
    [Abstract] [Full Text] [Related]

  • 5. Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.
    Jafri M, Douis H, Porfiri E.
    Clin Oncol (R Coll Radiol); 2008 Oct 31; 20(8):657-8. PubMed ID: 18644704
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tumour flare during interruption of temsirolimus treatment for metastatic renal cell cancer.
    Paterson C, Jones RJ.
    Clin Oncol (R Coll Radiol); 2009 Nov 31; 21(9):732-3. PubMed ID: 19665360
    [No Abstract] [Full Text] [Related]

  • 12. Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma.
    Rodríguez Faba O, Breda A, Rosales A, Palou J, Algaba F, Maroto Rey P, Villavicencio H.
    Eur Urol; 2010 Aug 31; 58(2):307-10. PubMed ID: 20347211
    [Abstract] [Full Text] [Related]

  • 13. Molecule of the month. Temsirolimus.
    Drug News Perspect; 2007 Aug 31; 20(6):406. PubMed ID: 17925894
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
    Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI, Dutcher J.
    Semin Oncol; 2009 Dec 31; 36 Suppl 3():S26-36. PubMed ID: 19963097
    [Abstract] [Full Text] [Related]

  • 16. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.
    De Masson A, Fouchard N, Méry-Bossard L, Dauendorffer JN.
    Dermatology; 2011 Dec 31; 223(1):4-8. PubMed ID: 21846963
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Temsirolimus for advanced renal cell carcinoma.
    Bergmann L, Maute L, Guschmann M.
    Expert Rev Anticancer Ther; 2014 Jan 31; 14(1):9-21. PubMed ID: 24313573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.